Paul Labinson, DO
Endocrinology, Diabetes & Metabolism · Nashua, NHNPI 1295782548
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,631 of the $4,869 with a category attached, or 74.6%. 31 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 31.3% of the total. Reporting peaked in 2019 at $3,729 and has fallen 97.4% since, to $96 in 2024. Among endocrinology, diabetes & metabolism clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $27.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$2K
- Dexcom, Inc.$578
- Amgen$479
- Lilly USA, LLC$347
- AstraZeneca$314
- Novo Nordisk$313
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$1,20025%
- Food & beverage$3,63175%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 16 | $1,522 |
| Dexcom, Inc. | 20 | $578 |
| Amgen(2 entities) | 20 | $479 |
| Lilly USA, LLC | 16 | $347 |
| AstraZeneca | 17 | $314 |
| Novo Nordisk | 21 | $313 |
| Sanofi-aventis U.S. LLC | 13 | $249 |
| Abbott | 6 | $134 |
| Medtronic | 6 | $110 |
| Johnson & Johnson | 5 | $83 |
| AbbVie | 5 | $74 |
| Boehringer Ingelheim | 3 | $69 |
| Companion Medical, Inc. | 3 | $55 |
| Merck | 3 | $49 |
| Amarin Pharma, Inc. | 3 | $47 |
| BD | 2 | $45 |
| Corcept Therapeutics | 2 | $43 |
| Lifescan, Inc. | 2 | $41 |
| IBSA Pharma Inc. | 2 | $40 |
| Insulet Corporation | 2 | $39 |
| Ascensia Diabetes Care US Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $30 |
| Valeritas, Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$1,319
- TEPEZZA$115
How this compares
$4,869 in reported general payments places this provider in the 90th percentile of 37 endocrinology, diabetes & metabolism providers in New Hampshire.
See all endocrinology, diabetes & metabolism providers in New Hampshire →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $152,424 |
| JardianceEmpagliflozin | 121 | $132,232 |
| TrulicityDulaglutide | 30 | $48,180 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $46,359 |
| MounjaroTirzepatide | 37 | $42,933 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $35,438 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $20,238 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $13,159 |
| JanuviaSitagliptin Phosphate | 12 | $12,150 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $10,870 |
| Novolog FlexpenInsulin Aspart | 31 | $9,733 |
| SynthroidLevothyroxine Sodium | 105 | $9,584 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $9,573 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 25 | $8,158 |
| Testosterone | 47 | $7,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $313 | $152,42492 claims |
| Boehringer IngelheimJardiance | $69 | $132,232121 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $347 | $94,88580 claims |
| MerckJanuvia | $49 | $12,15012 claims |
| AbbVieSynthroid | $74 | $9,584105 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $20 | $4,805336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 37 endocrinology, diabetes & metabolism providers in New Hampshire.
Other endocrinology, diabetes & metabolism in Nashua
- John PorembaNashua$493
- Elizabeth SpatolaNashua$485
- Ellie ChuangNashua$433
- Simona IojaNashua$93
- Margaret FlynnNashua$43
- Michael DavidsonDover$204K
- Matthew KamilConcord$163K
- Dylan ThomasDover$17K
- Sreenija SuryadevaraLebanon$4K
- Harpreet RaiLebanon$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.